

Genotype 1	Past Treatment?	Past Treatment Regimen	Current Treatment Options	Duration			
Non-cirrhotic	Naive	N/A	Elbasvir/Grazoprevir (Zepatier™)	Genotype 1a with NS5A RAV* add Ribavirin = 16 weeks	Genotype 1a without NS5A RAV* = 12 weeks	Genotype 1b = 12 weeks	
			Ledipasvir/Sofosbuvir (Harvoni®)	HCV RNA <6mil = 8 weeks**		HCV RNA >6mil = 12 weeks	
			Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira XR/Pak™)	Genotype 1a = 12wks add RBV			Genotype 1b = 12 weeks
			Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks			
			Simeprevir & Sofosbuvir (Olysio® & Sovaldi®)	12 weeks			
			Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®)	12 weeks			
	Experienced	Pegylated interferon & Ribavirin	Pegylated interferon & Ribavirin ± Protease Inhibitor	Same as non-cirrhotic, treatment naive			
				Ledipasvir/Sofosbuvir (Harvoni®)	12 weeks		
				Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks		
				Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®)	12 weeks		
				Elbasvir/Grazoprevir (Zepatier™) & Ribavirin	12 weeks	Genotype 1a with NS5A baseline RAV* = 16 weeks	
				Sofosbuvir & Ribavirin ± Pegylated interferon	Ledipasvir/Sofosbuvir (Harvoni®) + Ribavirin	12 weeks	
			NS5A Inhibitor or Simeprevir & Sofosbuvir (Olysio® & Sovaldi®)	STOP – Consult Liver Specialist			

*RAV = resistance associated variant

**Not recommended in persons with IL-28b polymorphism CT or TT, African Americans, or with HIV co-infection.

Genotype 1	Past Treatment?	Past Treatment Regimen	Current Treatment Options	Duration			
Cirrhosis	Naive	N/A	Elbasvir/Grazoprevir (Zepatier™)	Genotype 1a with NS5A RAV* add Ribavirin = 16 weeks	Genotype 1a without NS5A RAV* = 12 weeks	Genotype 1b = 12 weeks	
			Ledipasvir/Sofosbuvir (Harvoni®)	HCV RNA <6 mil = 8 weeks	HCV RNA >6 mil = 12 weeks		
			Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira XR/Pak™)	Genotype 1a = 24 weeks add Ribavirin			Genotype 1b = 12 weeks
			Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks			
			Simeprevir & Sofosbuvir (Olysio® & Sovaldi®)	12 weeks			
			Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®)	12 weeks			
	Experienced – Compensated Cirrhosis Only (Child-Pugh: Class A)	Pegylated interferon & Ribavirin	Elbasvir/Grazoprevir (Zepatier™)	Genotype 1a without NS5A RAV* = 12 weeks		Genotype 1b = 12 weeks	
			Ledipasvir/Sofosbuvir (Harvoni®) & Ribavirin	12 weeks			
			Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks			
			Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir (Viekira XR/Pak™)	12 weeks (Genotype 1b only)			
		Pegylated interferon & Ribavirin ± Protease Inhibitor	Ledipasvir/Sofosbuvir (Harvoni®)	With Ribavirin 12 weeks	Without Ribavirin 24 weeks		
			Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks			
			Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®) ± Ribavirin	24 weeks			
			Elbasvir/Grazoprevir (Zepatier™) & Ribavirin	12 weeks	Genotype 1a with baseline NS5A RAV* = 16 weeks		
Sofosbuvir & Ribavirin ± Pegylated interferon	Ledipasvir/Sofosbuvir (Harvoni®) & Ribavirin	24 weeks					
NS5A Inhibitor or Simeprevir & Sofosbuvir (Olysio® & Sovaldi®)	STOP – Consult Liver Specialist						
Decompensated Cirrhosis		STOP – Consult Liver Specialist					

*RAV = resistance associated variant

Genotype 2	Past Treatment?	Past Regimen	Current Treatment Options	Duration
Non-cirrhotic or Compensated Cirrhosis (Child-Pugh: Class A)	Naive	N/A	Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks
	Experienced	Pegylated interferon & Ribavirin	Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks
		Sofosbuvir & Ribavirin	Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®) ± Ribavirin	24 weeks
			Sofosbuvir/Velpatasvir (Epclusa®) + Ribavirin	12 weeks
Decompensated Cirrhosis		STOP – Consult Liver Specialist		

Genotype 3*	Past Treatment?	Past Regimen	Current Treatment Options	Duration	
Non-cirrhotic	Naive	N/A	Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®)	12 weeks	
			Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks	
	Experienced	Pegylated interferon & Ribavirin	Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®)	12 weeks	
			Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks	
		Sofosbuvir & Ribavirin	Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®) + Ribavirin	24 weeks	
			Sofosbuvir/Velpatasvir (Epclusa®) + Ribavirin	12 weeks	
Compensated Cirrhosis (Child Pugh: Class A)	Naïve	N/A	Sofosbuvir/Velpatasvir (Epclusa®)	12 weeks	
			Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®) ± Ribavirin	24 weeks	
	Experienced	Pegylated interferon & Ribavirin	Sofosbuvir/Velpatasvir (Epclusa®) + Ribavirin	12 weeks	
			Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®) + Ribavirin	24 weeks	
		Sofosbuvir & Ribavirin	Daclatasvir & Sofosbuvir (Daklinza™ & Sovaldi®) + Ribavirin	24 weeks	
			Sofosbuvir/Velpatasvir (Epclusa®) + Ribavirin	12 weeks	
	Decompensated Cirrhosis		STOP – Consult Liver Specialist		

***Preliminary data suggest that NS5A Genotype 3 resistance associated variant (RAV) testing is recommended for all genotype 3 patients prior to treatment.**